AbbVie

The cover story in this weekend's Barron's examines how blockchain technology is beginning to show promise. Other featured articles include income picks from top advisors and five standout dividend picks. Also, see the prospects for a trust and custodial bank and a leading telecom. "...

Benzinga has featured looks at many investor favorite stocks over the past week. Bullish calls included a leading big bank and an video streaming giant. Bearish calls included giants in tobacco and social media. The new earnings reporting season has gotten off to a strong start, offsetting the...

Insider buying can be an encouraging signal for potential investors. An activist investor took the next step in acquiring his target. Also, a couple of regular buyers returned to the buy windows this week. Conventional wisdom says that insiders and 10-percent owners really only buy shares of a...

Benzinga has featured looks at many investor favorite stocks over the past week. Bullish calls included a streaming video giant and a struggling social media player. Bearish calls included the iPhone maker and a leading pharmaceutical company. The Nasdaq ended May nearly 6 percent...

This weekend's Barron's cover story presents the findings of the latest Energy Roundtable. Other featured articles examine the prospects for a tech giant's quantum computing efforts and an industry leader with little to fear from Amazon. Also, Warren Buffett's latest annual...

Benzinga has featured a look at many investor favorite stocks over the past week. Bullish calls featured a top biotech, an online payment company and an energy infrastructure giant. Bearish calls included a leading coffee chain, REITs and a hotel operator in the news. Volatility came...

This weekend's Barron's cover story features the second part of the 2018 Barron's Roundtable feature. Each Roundtable panelist offers up a handful of recommendations and reasons why they like these particular picks now. Other featured articles include an investor's guide...

The preliminary success of a drug designed to combat idiopathic pulmonary fibrosis could give Galapagos NV (ADR) (NASDAQ: GLPG) a 10-percent boost, according to Morgan Stanley. A 23-person study of the drug GLPG1690, an autotaxin inhibitor, found that patients had better lung function than those...

Three leading biotech companies will step into the earnings spotlight this week. Consensus forecasts from Wall Street analysts call for earnings growth from just two of them. And only one of them has topped estimates by double-digits in recent quarters. While the biotechnology industry has had a...

The three largest biotechs are set to share their latest quarterly results this week. Wall Street analysts are looking for solid to strong growth from all three. However, expectations are lower for many other biotech and pharmaceutical companies reporting this week. The three largest public...